The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2022 Dec 23

PMID 36561983

Authors

Chun-Lu Shu

Yu-Ling Liu

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: To summarize the targeted therapies and immunotherapy of Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant non-small cell lung cancer (NSCLC), and discuss the ongoing clinical trials.

Recent Findings: KRAS mutations occur in about 30% of patients with NSCLC and are the second most frequent genetic variation in lung cancer. It has been considered "undruggable" for 40 years until the discovery of a direct inhibitor of KRAS G12C. The promising direct KRAS G12C inhibitors such as sotorasib and MRTX849 have made a breakthrough with promising anti-tumor effects in patients with KRAS G12C-mutant advanced/metastatic NSCLC post one prior line of therapy. Following the success of immune checkpoint inhibitors (ICIs) in NSCLC, many patients harboring KRAS mutations can benefit from ICIs. However, due to disease heterogeneity, the prognosis of patients remains unsatisfactory, leaving room for personalized treatment options, such as new targeted therapies and other therapies.

Summary: In this review, we aim to dissect the strategies of clinical trials in these tumors, shifting from a few chemotherapy options to targeted and immunotherapy, in the context of molecular selection of KRAS-mutant NSCLC subtypes.

Citing Articles

Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.

Bteich F, Mohammadi M, Li T, Ahmed Bhat M, Sofianidi A, Wei N Int J Mol Sci. 2023; 24(15).

PMID: 37569406 PMC: 10418782. DOI: 10.3390/ijms241512030.

Advances in the Molecular Landscape of Lung Cancer Brain Metastasis.

Souza V, de Araujo R, Santesso M, Seneda A, Minutentag I, Felix T Cancers (Basel). 2023; 15(3).

PMID: 36765679 PMC: 9913505. DOI: 10.3390/cancers15030722.

References

Fell J, Fischer J, Baer B, Blake J, Bouhana K, Briere D . Identification of the Clinical Development Candidate , a Covalent KRAS Inhibitor for the Treatment of Cancer. J Med Chem. 2020; 63(13):6679-6693. DOI: 10.1021/acs.jmedchem.9b02052. View

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

Zhang J, Zhang J, Liu Q, Fan X, Leung E, Yao X . Resistance looms for KRAS G12C inhibitors and rational tackling strategies. Pharmacol Ther. 2021; 229:108050. DOI: 10.1016/j.pharmthera.2021.108050. View

Hong D, Fakih M, Strickler J, Desai J, Durm G, Shapiro G . KRAS Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020; 383(13):1207-1217. PMC: 7571518. DOI: 10.1056/NEJMoa1917239. View

Skoulidis F, Li B, Dy G, Price T, Falchook G, Wolf J . Sotorasib for Lung Cancers with p.G12C Mutation. N Engl J Med. 2021; 384(25):2371-2381. PMC: 9116274. DOI: 10.1056/NEJMoa2103695. View

Zhang X, Wang J, Shao G, Wang Q, Qu X, Wang B . Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nat Commun. 2019; 10(1):1772. PMC: 6467893. DOI: 10.1038/s41467-019-09762-1. View

Canon J, Rex K, Saiki A, Mohr C, Cooke K, Bagal D . The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019; 575(7781):217-223. DOI: 10.1038/s41586-019-1694-1. View

Warren G, Cummings K . Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. Am Soc Clin Oncol Educ Book. 2013; :359-64. DOI: 10.14694/EdBook_AM.2013.33.359. View

Nagasaka M, Azmi A . Clinical progress of KRAS-targeted therapies: what next?. Future Med Chem. 2022; 14(15):1107-1110. DOI: 10.4155/fmc-2022-0128. View

10.

Ostrem J, Peters U, Sos M, Wells J, Shokat K . K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013; 503(7477):548-51. PMC: 4274051. DOI: 10.1038/nature12796. View

11.

Landre T, Justeau G, Assie J, Chouahnia K, Davoine C, Taleb C . Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer Immunol Immunother. 2021; 71(3):719-726. PMC: 10992001. DOI: 10.1007/s00262-021-03031-1. View

12.

Briere D, Li S, Calinisan A, Sudhakar N, Aranda R, Hargis L . The KRAS Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. Mol Cancer Ther. 2021; 20(6):975-985. PMC: 8444277. DOI: 10.1158/1535-7163.MCT-20-0462. View

13.

Moore A, Rosenberg S, McCormick F, Malek S . Author Correction: RAS-targeted therapies: is the undruggable drugged?. Nat Rev Drug Discov. 2020; 19(12):902. DOI: 10.1038/s41573-020-0089-1. View

14.

Janne P, Riely G, Gadgeel S, Heist R, Ou S, Pacheco J . Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation. N Engl J Med. 2022; 387(2):120-131. DOI: 10.1056/NEJMoa2204619. View

15.

Arbour K, Jordan E, Kim H, Dienstag J, Yu H, Sanchez-Vega F . Effects of Co-occurring Genomic Alterations on Outcomes in Patients with -Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2017; 24(2):334-340. PMC: 5771996. DOI: 10.1158/1078-0432.CCR-17-1841. View

16.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

17.

Desage A, Leonce C, Swalduz A, Ortiz-Cuaran S . Targeting Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies. Front Oncol. 2022; 12:796832. PMC: 8889932. DOI: 10.3389/fonc.2022.796832. View

18.

Baud V, Karin M . Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009; 8(1):33-40. PMC: 2729321. DOI: 10.1038/nrd2781. View

19.

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

20.

Nassar A, Adib E, Kwiatkowski D . Distribution of Somatic Mutations across Race, Sex, and Cancer Type. N Engl J Med. 2021; 384(2):185-187. DOI: 10.1056/NEJMc2030638. View